Fertility Protection in Female Oncology Patients: How Should Patients Be Counseled?

Overview

Journal Geburtshilfe Frauenheilkd

Specialty Gynecology & Obstetrics

Date 2016 Jan 5

PMID 26726265

Citations 8

Authors

S Findeklee

L Lotz

K Heusinger

I Hoffmann

R Dittrich

M W Beckmann

Affiliations

Soon will be listed here.

Abstract

Protecting the fertility of patients with oncologic disease is becoming more and more important, as fulfilling the wish to have children is increasingly occurring at a later stage in life and long-term survival rates after cancer are continuing to improve. A number of fertility-preserving options exist. In addition to techniques which have been around for some time such as medical ovarian suppression, ovarian transposition, and organ-preserving surgery, there are other, more recent, innovative methods which have developed over the last few years such as cryopreservation of oocytes or ovarian tissue transplantation after completing cancer therapy. As every procedure has its specific advantages and disadvantages, informed patient consent is essential. The physician's aim must be to select the optimal procedure for each patient. The extent of patients' information about the options to preserve fertility in women with oncologic disease remains limited. One of the main reasons for this is that clinicians are not sure how to inform patients about existing procedures and methods. The aim of this review article is to provide help in clinical practice.

Citing Articles

Fertility Preservation in Cervical Cancer-Treatment Strategies and Indications.

Salman L, Covens A Curr Oncol. 2024; 31(1):296-306.

PMID: 38248104 PMC: 10814061. DOI: 10.3390/curroncol31010019.

WOMEN AND MEN WITH CANCER AND A FUTURE DESIRE FOR CHILDREN - WHAT SHOULD CLINICIANS CONSIDER IN COVID-19 PANDEMIC TIMES?.

Findeklee S, Kasoha M, Radosa J, Radosa M, Hamoud B, Sima R Acta Endocrinol (Buchar). 2021; 17(2):234-240.

PMID: 34925573 PMC: 8665243. DOI: 10.4183/aeb.2021.234.

The Pathophysiological Role of CoA.

Czumaj A, Szrok-Jurga S, Hebanowska A, Turyn J, Swierczynski J, Sledzinski T Int J Mol Sci. 2020; 21(23).

PMID: 33260564 PMC: 7731229. DOI: 10.3390/ijms21239057.

Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.

Ruddy K, Schaid D, Partridge A, Larson N, Batzler A, Haberle L Fertil Steril. 2019; 112(4):731-739.e1.

PMID: 31371054 PMC: 6765404. DOI: 10.1016/j.fertnstert.2019.05.018.

Repetitive Maturation of Oocytes From Non-Stimulated Xenografted Ovarian Tissue From a Prepubertal Patient Indicating the Independence of Human Ovarian Tissue.

Raffel N, Lotz L, Hoffmann I, Liebenthron J, Soder S, Beckmann M Geburtshilfe Frauenheilkd. 2017; 77(12):1304-1311.

PMID: 29269958 PMC: 5734935. DOI: 10.1055/s-0043-122601.

References

WHITTINGHAM D . In-vitro fertilization, embryo transfer and storage. Br Med Bull. 1979; 35(2):105-11. DOI: 10.1093/oxfordjournals.bmb.a071556. View

Blumenfeld Z, von Wolff M . GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update. 2008; 14(6):543-52. DOI: 10.1093/humupd/dmn022. View

Cobo A, Meseguer M, Remohi J, Pellicer A . Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010; 25(9):2239-46. DOI: 10.1093/humrep/deq146. View

Loizzi V, Selvaggi L, Leone L, Latorre D, Scardigno D, Magazzino F . Borderline epithelial tumors of the ovary: Experience of 55 patients. Oncol Lett. 2015; 9(2):912-914. PMC: 4301501. DOI: 10.3892/ol.2014.2758. View

Mattle V, Behringer K, Engert A, Wildt L . Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl. 2005; (66):77-82. DOI: 10.1111/j.1600-0609.2005.00459.x. View

Hauerberg L, Hogdall C, Loft A, Ottosen C, Bjoern S, Mosgaard B . Vaginal Radical Trachelectomy for early stage cervical cancer. Results of the Danish National Single Center Strategy. Gynecol Oncol. 2015; 138(2):304-10. DOI: 10.1016/j.ygyno.2015.05.016. View

Newman H, Finger P, Chin K, Pavlick A . Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol. 2011; 21(6):796-801. DOI: 10.5301/EJO.2011.6477. View

Abusief M, Missmer S, Ginsburg E, Weeks J, Partridge A . The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010; 116(4):791-8. DOI: 10.1002/cncr.24835. View

Parulekar W, Day A, Ottaway J, Shepherd L, Trudeau M, Bramwell V . Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol. 2005; 23(25):6002-8. DOI: 10.1200/JCO.2005.07.096. View

10.

Schultheis B, Nijmeijer B, Yin H, Gosden R, Melo J . Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 2011; 36(3):271-4. DOI: 10.1016/j.leukres.2011.09.025. View

11.

Zapardiel I, Diestro M, Aletti G . Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol. 2013; 40(4):387-93. DOI: 10.1016/j.ejso.2013.11.028. View

12.

von Wolff M, Thaler C, Frambach T, Zeeb C, Lawrenz B, Popovici R . Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2008; 92(4):1360-1365. DOI: 10.1016/j.fertnstert.2008.08.011. View

13.

Lotz L, Montag M, van der Ven H, von Wolff M, Mueller A, Hoffmann I . Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice--no evidence of malignant cell contamination. Fertil Steril. 2011; 95(8):2612-4.e1. DOI: 10.1016/j.fertnstert.2011.05.003. View

14.

Donnez J, Dolmans M, Demylle D, Jadoul P, Pirard C, Squifflet J . Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004; 364(9443):1405-10. DOI: 10.1016/S0140-6736(04)17222-X. View

15.

Perez-Fidalgo J, Rosello S, Garcia-Garre E, Jorda E, Martin-Martorell P, Bermejo B . Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2009; 120(1):245-51. DOI: 10.1007/s10549-009-0426-x. View

16.

Stoop D, van der Veen F, Deneyer M, Nekkebroeck J, Tournaye H . Oocyte banking for anticipated gamete exhaustion (AGE) is a preventive intervention, neither social nor nonmedical. Reprod Biomed Online. 2014; 28(5):548-51. DOI: 10.1016/j.rbmo.2014.01.007. View

17.

Alvarez R, Vazquez-Vicente D . Fertility sparing treatment in borderline ovarian tumours. Ecancermedicalscience. 2015; 9:507. PMC: 4335965. DOI: 10.3332/ecancer.2015.507. View

18.

Dittrich R, Maltaris T, Hoffmann I, Oppelt P, Beckmann M, Mueller A . Fertility preservation in cancer patients. Minerva Ginecol. 2010; 62(1):63-80. View

19.

Cobo A, Vajta G, Remohi J . Vitrification of human mature oocytes in clinical practice. Reprod Biomed Online. 2009; 19 Suppl 4:4385. View

20.

Morice P, Castaigne D, Haie-Meder C, Gerbaulet A, Pautier P, Duvillard P . Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod. 1998; 13(3):660-3. DOI: 10.1093/humrep/13.3.660. View